Toda la actualidad y última hora sobre Grünenthal.

Recibe en tu correo las noticias sobre Grünenthal apuntándome a nuestro boletín informativo personalizado.


COMUNICADO: Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to $ 500 million

Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal’s investigational medicine Resiniferatoxin (“RTX”). Shionogi obtained the exclusive rights to commercialise Grünenthal’s asset in Japan for pain associated with osteoarthritis of the knee.
Boletín Grünenthal

Recibe las últimas noticias sobre Grünenthal